Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAG for Implant Osseointegration
NCT07060859Completed
- Start
- Jan 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Randomised, single-blind trial of dexamethasone iontophoretic patch, ascorbic acid and beta-sodium glycerophosphate in tooth loss (2 arms). Primary endpoint: Implant Stability Quotient at 16 weeks. Started Jan 2023; status: completed.
02
Drugs
dexamethasone iontophoretic patchascorbic acidbeta-sodium glycerophosphate
03
Conditions
tooth loss
Beyond the preview
Go deeper on NCT07060859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07060859.